
30th January 2023

ASX:GLH

Global Health Ltd December 2022

Quarterly Business Activity Report & Appendix 4C

Melbourne, Australia – Healthcare software provider **Global Health Ltd (ASX: GLH)** ("Global Health") is pleased to release its **Appendix 4C Cash Flow Report** for the quarter ended 31 December 2022, along with a **Quarterly Business Activity Report**.

Financial Overview

- The net operating cashflow deficit for the quarter has reduced from \$1.706M in the September Quarter to \$0.70m in the Dec Quarter. Given the continued uncertain global economic outlook, the Group is focused on returning to positive Net operating cashflow by June 2023
 - The net investing cashflow deficit is largely steady across both the December and September Quarters at an average of \$450K per quarter. This investment is directed to the transition of our client/server platforms to the next generation, multi-tenanted (SaaS) platform for healthcare providers (MasterCare Plus), and consumer applications focused on empowered and engaged consumers working with their clinical care teams for improved health outcomes.
 - The repayment of borrowings to HP Financial Services will be completed by June 2023 leaving the Company debt free
 - The Company has restructured its Australian operations to reduce costs and focus on the delivery of existing contracts. The benefits of this restructure will flow through in the next 6 months and beyond and enable the Australian operations to be operating cashflow positive by June 2023
 - The sales pipeline remains healthy as healthcare organisations are seeking to improve their productivity and efficiencies. Their decision-making process has slowed due to a lack of resources and the increase in demand pressures in a post Covid-19 healthcare environment.
-

In accordance with Listing Rule 4.7C.1, the expenditures of Global Health for the quarter ended 31 December 2022 are set out in the table below:

Expense Category	Amount (\$A'000)
Product manufacturing and operating costs	464
Advertising and marketing	93
Leased Assets	46
Staff costs	2,015
Administration and corporate costs	284
Interest and other costs of finance paid	2
Property, plant and equipment	4
Research and product development	472
Repayment of borrowings (HP Finance)	34

In accordance with Listing Rule 4.7C.3, payments to related parties and their associates during the quarter totalled \$104K. This related to directors' remuneration.

New Contracts

In the December quarter, new contracts were executed as follows:

- The Acurio Health Group - currently comprising five industry-leading hospitals, clinics and research centres located across Sydney. All strive to be at the forefront of the latest medical research, treatments, and procedures with the aim of providing the highest quality holistic healthcare to the community. Acurio will be implementing MasterCare PAS and MasterCare Inpatient EMR at their new facility in Sydney
- The Doncaster Private Hospital - a new state of the art facility in Melbourne has selected MasterCare PAS for implementation
- New MasterCare Discharge Summary contracts have been executed for implementation at the following Hospital clients:
 - Alwyn Rehabilitation Private Hospital, NSW
 - East Sydney Private Hospital, NSW
 - Euroa Health Private Hospital, Victoria
 - Northeast Community Private Hospital, South Australia
 - Wesley Mission Private hospital, NSW

Forward Outlook & Growth Strategy

The investments in upgraded platforms are on track to generate new revenues in the March-23 quarter with the initial deployments in the hospitals deals referred to above.

Our Australian operations start the new year with a backlog of project delivery commitments. Implementation of MasterCare at Latrobe Community Health was delayed in the 6 months to Dec-23 due to client resourcing issues. Implementation will commence in the March-23 quarter.

Latrobe Community Health is in the process of a major shift in their engagement of internal work practices with a specific focus on reaching their local community with the Group's MasterCare application which minimises manual tasks and reduces the use of paper forms. This will enable them to focus the organisation's energies on providing exceptional care for their clients and the community.

Business development activity across the ASEAN markets is translating into a healthy pipeline of opportunities. These are expected to translate into positive cashflow for overseas operations by Dec-23.

The Group also continues to explore M&A opportunities with synergistic organisations.

This announcement was approved for lodgement by the Board.

– ENDS –

For further information please contact:

Mathew Cherian

Managing Director, Global Health Limited

M: 0409 099 788

E: Mathew.cherian@global-health.com

Rod North - Investor Relations, Media & PR

Managing Director, Bourse Communications

M: 0408 670 706

E: rod@boursecommunications.com.au

About Global Health Limited

Global Health (ASX: GLH) is a leading provider of Digital Health solutions to the Australian Healthcare Industry. Innovation, consumer-centricity and connectivity are the foundations of the Company's vision of 'Connecting Clinicians and Consumers.'

Global Health helps streamline the delivery of healthcare services and provide better health outcomes across various health sectors, including acute and community settings.

Global Health offers a range of tailored software and SaaS solutions helping health businesses to be more efficient and deliver excellent patient care. These include electronic medical records for health delivery organisations, client management systems for community health, patient administration systems for hospitals, practice management systems, secure messaging for connected care, patient engagement platforms and consumer health records.

Located in Melbourne, Victoria the company is ISO27001 compliant.

Find out more about Global Health Solution's at www.global-health.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Global Health Limited

ABN		Quarter ended ("current quarter")	
		31 December 2022	
75 091 377 892		Current quarter \$A'000	Year to date (6 months) \$A'000
Consolidated statement of cash flows			
1.1	Receipts from customers	2,200	3,381
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(464)	(1,318)
	(c) advertising and marketing	(93)	(157)
	(d) leased assets	(46)	(92)
	(e) staff costs	(2,015)	(3,621)
	(f) administration and corporate costs	(284)	(599)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	(2)	(5)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	(704)	(2,411)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(4)	(8)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	(472)	(884)
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	(11)
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(476)	(903)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	338	338
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(34)	(69)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	304	269

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,221	6,376
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(704)	(2,411)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(476)	(903)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	304	269
4.5	Effect of movement in exchange rates on cash held	(25)	(11)
4.6	Cash and cash equivalents at end of period	3,320	3,320

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	3,320	4,221
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,320	4,221

6. Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1 *	104
6.2 Aggregate amount of payments to related parties and their associates included in item 2 **	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

** Payments associated with item 6.1 relate to directors' fees/directors' remuneration.*

***Payments associated with item 6.2 relate to a loan to an associate company.*

7.	Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
	<p><i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i></p> <p><i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i></p>		
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	25	19
7.3	Other (please specify)	72	72
7.4	Total financing facilities	97	91
7.5	Unused financing facilities available at quarter end		6
7.6	<p>Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</p>		
	<p>7.2 Lender: Australia and New Zealand Banking Group Limited (ANZ) Company Credit Card Facility Interest rate: Up to 8-week Interest free period. Otherwise, 17.74% per annum on purchases if unpaid by the due date. 19.24% per annum on cash advances. Secured/unsecured: Unsecured</p> <p>7.3 Lender: HP Financial Services (Australia) Pty Ltd Interest rate: 8.5% per annum Maturity date: June 2023 Secured/unsecured: Unsecured</p>		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(704)
8.2 Cash and cash equivalents at quarter end (item 4.6)	3,320
8.3 Unused finance facilities available at quarter end (item 7.5)	6
8.4 Total available funding (item 8.2 + item 8.3)	3,326
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.72
<p><i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i></p>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
<p>Answer: N/A</p>	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
<p>Answer: N/A</p>	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
<p>Answer: N/A</p>	
<p><i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i></p>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **30th** January 2023

Authorised by: Board of Directors

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
-